Multi drug and other forms of drug resistant tuberculosis are uncommon among treatment naïve tuberculosis patients in Tanzania

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Nagu, Tumaini J ^a,b   Aboud, Said ^a   Mwiru, Ramadhani ^c   Matee, Mecky ^a   Fawzi, Wafaie ^d   Mugusi, Ferdinand ^a  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MANAGEMENT AND DEVELOPMENT FOR HEALTH   (Tanzania)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; DRUG RESISTANT TUBERCULOSIS; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; SPUTUM SMEAR; TANZANIA; CROSS-SECTIONAL STUDY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PROSPECTIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

CORYNEBACTERINEAE;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; TANZANIA; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84929483928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118601     Document Type: Article

References (22)

1. World Health Organisation. Global tuberculosis report. World Health Organisation 2013; 1-22. Available: http://www.ho.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf
2. World Health Organisation. Antimicrobial resistance: Global report on surveillance. World Health Organisation 2014; 43-47. Available: http://www.who.int/iris/bitstream/10665/112642/1/9789241564748-eng.pdf
3. Dooley K, Obuku E, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL, et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?J Infect Dis 2013; 207: 1352-1358. doi: 10.1093/infdis/jis460 PMID: 22807518
4. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bulletin of the World Health Organization 2014; 90: 111-119.
5. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance Lancet 2009; 373: 1861-1873. doi: 10.1016/S0140-6736(09)60331-7 PMID: 19375159
6. World Health Organization. Anti-tuberculosis drug resistance in the world: WHO-IUTALD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. World Health Oganisation 4th report. 2008. Available: http://www.who.int/tb/publications/2008/drs-report4-26feb08.pdf
7. Lukoye D, Adatu F, Musisi K, Kasule GW, Were W, Odeke R, et al. Anti-tuberculosis drug resistance among new and previously treated sputum smear-positive tuberculosis patients in Uganda: results of the first national survey. PLoS One 2013; 8: e70763. doi: 10.1371/journal.pone.0070763 PMID: 23936467
8. Sanchez-Padilla E, Ardizzoni E, Sauvageot D, Ahoua L, Martin A, Varaine F, et al. (2013) Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions. Int J Tuberc Lung Dis 17: 1036-1042. doi: 10.5588/ijtld.12.0842 PMID: 23827027
9. Urassa W, Mugusi F, Villamor E, Msamanga G, Moshiro C, Bosch R, et al. Primary antimicrobial resistance among Mycobacterium tuberculosis isolates from HIV seropositive and HIV seronegative patients in Dar es Salaam Tanzania. BMC Res Notes 2008; 1: 58. doi: 10.1186/1756-0500-1-58 PMID: 18710511
10. Kibiki G, Mulder B, DolmansW, de Beer J, Boeree M, Sam N, et al. M tuberculosis genotypic diversity and drug susceptibility pattern in HIV infected and non-HIV-infected patients in northern Tanzania. BMC Microbiol 2007; 7: 51. PMID: 17540031
11. Matee M, Mfinanga S, Holm-Hansen C. Anti-TB drug resistance levels and patterns among Mycobacterium tuberculosis isolated from newly diagnosed cases of pulmonary tuberculosis in Dar es Salaam, Tanzania. APMIS 2009; 117: 263-267. doi: 10.1111/j.1600-0463.2008.02429.x PMID: 19338514
12. Yang Z, Mtoni I, Chonde M, Mwakasekage M, Fuursted K, Askgård DS, et al. DNA fingerprinting and phenotyping of Mycobacterium tuberculosis isolates from human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients in Tanzania. J Clin Microbio 1995; 33: 1064-1069. PMID: 7615706
13. Chonde T, Doulla B, Mfinanga S, Range N, Lwilla F, Shirima RP, et al. National anti-tuberculosis drug resistance study in Tanzania. Int J Tuberc Lung Dis 2010; 14: 967-972. PMID: 20626940
14. Bernard C, Brossier F, Sougakoff W, Veziris N, Frechet-Jachym M, Metivier N, et al. A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. Euro Surveill 2013; 18: 20555. PMID: 23968874
15. Kruijshaar M, Watson J, Drobniewski F, Anderson C, Brown T, Magee JG, et al. Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. BMJ 2008; 336: 1201-1202. doi: 10.1136/bmj.39560.630613.80 PMID: 18456592
16. van Heurck R, Payen MC, De Wit S, Clumeck N. Epidemiology of MDR-TB in a Belgian infectious diseases unit: a 15 years review. Acta Clin Belg 2013; 68: 321-324. PMID: 24579238
17. Ministry of Health and Social Welfare. Manual of the National Tuberculosis and Leprosy programme in Tanzania, 5th edition. Dar es Salaam, Tanzania.
18. Nagu T, Spiegelman D, Hertzmark E, Aboud S, Makani J, Matee MI, et al. Anemia at the initiation of tuberculosis therapy is associated with delayed sputum conversion among pulmonary tuberculosis patients in Dar-es-Salaam, Tanzania. PLoS One 2014; 9(3):e91229. doi: 10.1371/journal.pone.0091229 PMID: 24642636
19. Ministry of Health and Social Welfare. National Tuberculosis and Leprossy Programme annual report, 2012. Dar es Salaam, Tanzania.
20. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis - 4th ed. WHO/HTM/TB/2009.422, Available: http://whqlibdoc.who.int/publications/2009/9789241598675-eng.pdf
21. Ministry of Health and Social Welfare. National guidelines for the management of HIV and AIDS, 3rd edition, 2012. Dar Es Salaam, Tanzania.
22. Satti H, McLaughlin MM, Seung KJ, Becerra MC, Keshavjee S. High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting. Int J Tuberc Lung Dis 2013; 17: 100-106. doi: 10.5588/ijtld.12.0344 PMID: 23232009